AATec Medical, a Munich, Germany-based biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), raised EUR2.7M in Seed funding.
The round saw participation from private investors, industry experts and family offices.
The company intends to use the funds to scale up its technology, expand the team and prepare for clinical studies expected to start in 2024.
Led by CEO Dr. Rüdiger Jankowsky, AATec Medical is a biotechnology company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections and rare diseases. It has demonstrated proof-of-principle in several indications and is currently preparing for a proof-of-concept clinical trial with the first product candidate ATL-105 for inhaled application in respiratory diseases.
Clinical studies are expected to start in first half of 2024. The long-term R&D strategy includes further conditions such as transplant, AAT deficiency and systemic inflammatory diseases.
FinSMEs
17/07/2023